Zacks Research Has Pessimistic Outlook of Neogen Q2 Earnings

Neogen Corporation (NASDAQ:NEOG) – Research analysts at Zacks Research dropped their Q2 2026 earnings per share estimates for shares of Neogen in a research report issued on Wednesday, December 17th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.06 for the quarter, down from their prior estimate of $0.07. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen’s FY2026 earnings at $0.25 EPS and Q2 2027 earnings at $0.08 EPS.

Several other analysts have also recently issued reports on NEOG. Wall Street Zen raised shares of Neogen from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Piper Sandler set a $6.50 price target on Neogen and gave the company a “neutral” rating in a research report on Thursday, October 16th. CJS Securities raised Neogen from a “market perform” rating to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday, December 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neogen in a research note on Monday, December 15th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.83.

Neogen Price Performance

Shares of NASDAQ NEOG opened at $7.13 on Monday. The firm has a 50-day simple moving average of $6.25 and a 200-day simple moving average of $5.68. The company has a quick ratio of 2.26, a current ratio of 3.58 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -1.49 and a beta of 1.99. Neogen has a 52 week low of $3.87 and a 52 week high of $13.40.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Inspire Investing LLC lifted its position in Neogen by 100.2% in the second quarter. Inspire Investing LLC now owns 93,416 shares of the company’s stock valued at $447,000 after buying an additional 46,753 shares during the last quarter. Invesco Ltd. raised its stake in shares of Neogen by 35.9% in the 1st quarter. Invesco Ltd. now owns 870,824 shares of the company’s stock valued at $7,550,000 after acquiring an additional 230,201 shares during the period. Grandeur Peak Global Advisors LLC lifted its holdings in shares of Neogen by 27.4% in the 2nd quarter. Grandeur Peak Global Advisors LLC now owns 895,811 shares of the company’s stock worth $4,282,000 after acquiring an additional 192,426 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Neogen by 171.2% during the 2nd quarter. Bank of Montreal Can now owns 110,406 shares of the company’s stock worth $528,000 after purchasing an additional 69,703 shares during the period. Finally, Values First Advisors Inc. increased its holdings in Neogen by 269.6% in the 2nd quarter. Values First Advisors Inc. now owns 109,907 shares of the company’s stock valued at $525,000 after purchasing an additional 80,171 shares during the last quarter. 96.73% of the stock is currently owned by hedge funds and other institutional investors.

Neogen Company Profile

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user?friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.